Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
LPCN 1144
HSMN NewsFeed - 31 Oct 2024
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO(R) in South Korea
Biopharmaceuticals
Licensing
Distribution
HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
Biopharmaceuticals
FDA
HSMN NewsFeed - 24 Feb 2020
Lipocine Announces Regulatory Path Forward for TLANDO(TM) Resubmission
Biopharmaceuticals
FDA
HSMN NewsFeed - 11 Nov 2019
Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA
Biopharmaceuticals
FDA
HSMN NewsFeed - 27 Aug 2019
Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction
Biopharmaceuticals
Litigation
HSMN NewsFeed - 23 Jul 2019
Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population
Biopharmaceuticals
FDA
HSMN NewsFeed - 14 Feb 2019
Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
Biopharmaceuticals
FDA
Return to NewsFeed
